A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease

Study acronym: NEPHRON
StatusWithdrawn
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status changed: Recruiting → Withdrawn Sponsor's reason: No recruitment Show 5 more changesShow less
    • Enrollment target: estimated 30 to confirmed 0
    • Primary completion date changed from estimate of Jul 2026 to Sep 17, 2026
    • Start date: Dec 1, 2025 to May 1, 2025
    • Eligibility criteria expanded, about 28 words
    • Site details revised
  2. 2 versions Re-verified since Jan 5, 2026, no change to tracked fieldsv2-v3
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
A study Comparing the Clinical Benefit of Finerenone Versus a Fixed-Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients with Hypertension and Chronic Kidney Disease.
Trial Details
NCT Number NCT07223502
Lead Sponsor Sarfez Pharmaceuticals, Inc.
Conditions
(from sponsor)		 Hypertension (HTN)
Related terms Hypertension
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov